RecruitingNCT06885905

Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

Sponsor

Imperial College London

Enrollment

100 participants

Start Date

Nov 27, 2024

Study Type

OBSERVATIONAL

Conditions

Chronic Pulmonary Aspergillosis

Summary

To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

All patients \>/= 18 years old and able to provide informed consent
Patients with a diagnosis of chronic pulmonary aspergillosis
To speak and understand English
Able to provide informed consent

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Ninewells Hospital & Medical School

Dundee, United Kingdom

Imperial College London

London, United Kingdom

Manchester NHS Foundation Trust

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06885905

Related Trials

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT0679455437 locations

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

NCT062449791 location

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study

NCT056531931 location

Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole

NCT036560811 location

A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis

NCT064474021 location